Innovent Biologics (1801 HK) - Have the Genes to Become a Big Pharma
This article mainly analyzed Innovent in terms of its current listed products (Sintilimab, Bevacizumab, Adalimumab and Rituximab), its pipeline,...
401 Views
Pre-IPO Adagene Inc (ADAG US) - Advanced Technology but Still Take Time for Commercialization
This article analyzed Adagene Inc. in terms of the DPL platform, the core products in the pipeline (ADG106, ADG126 and ADG116), the financial...
296 Views
BeiGene: Cancer Treatment in China--The Underestimated Opportunity
We think that cancer is underdiagnosed and undertreated in China. We analyze the data and propose two approaches for investing in this theme.
339 Views
Akeso (康方生物) Placement - Prepping for Commercialization
Akeso Biopharma Inc (9926 HK) is looking to raise about US$154m from its primary placement to fund its expansion plans which includes building comm...
345 Views
Stock Connect - Secondary Listings and Biotech Stocks to Become Eligible?
A rule change that admits Secondary listings and Chapter 18A listed Biotech stocks to the Southbound Stock Connect could see Alibaba, JD and...
469 Views